Mohammad Imran Siddiqi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mohammad Imran Siddiqi has a total of 226 co-authors. Here are the top co-authors by number of shared publications:
Shakil Ahmed
Biochemistry and Structural Biology Division, CSIR-Central Drug Research Institute, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow, 226031, India
10 shared publicationsKushagra Kashyap
CSIR-Central Drug Research Institute (CSIR-CDRI)
5 shared publicationsShagun Krishna
Molecular & Structural Biology Division, CSIR-Central Drug Research Institute , Lucknow , India
5 shared publicationsVikash Kumar
Molecular and Structural Biology Division , CSIR-Central Drug Research Institute (CSIR-CDRI) , Sector 10, Jankipuram Extension, Sitapur Road , Lucknow 226031 , India
5 shared publicationsJitendra Kuldeep
Biochemistry and Structural Biology Division, CDRI, Lucknow 226031, India
4 shared publicationsNidhi Singh
Molecular and Structural Biology Division, CSIR-Central Drug Research Institute, B.S. 10/1, sector 10, Jankipuram Extension, Sitapur Road, Lucknow, Uttar Pradesh, 226031, India
4 shared publications
Latest Publications
- 22 January 2026
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 203, 111481
Graph neural network-guided identification and biological evaluation of potential AKT1 inhibitors for triple-negative breast cancer
- 22 January 2026
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 203, 111481
Graph neural network-guided identification and biological evaluation of potential AKT1 inhibitors for triple-negative breast cancer
- 4 November 2025
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 39 (2) , 1-14
Mycobacterium tuberculosis FAS-II pathway targeted integrative deep learning based identification of potential anti-tubercular agents
Mycobacterium tuberculosis (Mtb) continues to be one of the major contributors to the global burden of infectious diseases. Many drugs used in the current treatment regime have fallen prey to the puzzling phenomenon of antimicrobial resistance. Despite various attempts, few recent drugs have been developed against the bacterium (Sharma A, Vadodariya PK, Vaddoriya VN, Dhameliya TM (2025) Comprehensive updates on antitubercular endeavors identified in 2023. Synlett 36:2393–2410. https://doi.org/10.1055/a-2595-8032; Patel KI, Saha N, Dhameliya TM, Chakraborti AK (2025) Recent advancements in the quest of Benzazoles as anti-Mycobacterium tuberculosis agents. Bioorg Chem 155:108093. https://doi.org/10.1016/j.bioorg.2024.108093; Dhameliya TM, Bhakhar KA, Gajjar ND, Patel KA, Devani AA, Hirani RV (2022) Recent advancements and developments in search of anti-tuberculosis agents: a quinquennial update and future directions. J Mol Struct 1248:131473. https://doi.org/10.1016/j.molstruc.2021.131473). The proteins involved in Mtb’s fatty acid synthase II (FAS-II) system are suitable drug targets. Many of the enzymes in this pathway, like β-ketoacyl-acyl carrier protein (KasA), 3-oxoacyl-[acyl-carrier-protein] synthase II (KasB) and β-ketoacyl-[acyl-carrier-protein] synthase III (FabH), are indispensable to Mtb but have no counterpart in humans. Here, we present an integrative approach starting with the curation of site specific dataset, exploratory data analysis with multiple machine learning models, virtual screening of compound library with hypertuned artificial neural networks (ANN) having hidden layers, molecular docking studies and in vitro validation to target some of the key elements involved in the mycolic acid chain elongation step during biosynthesis. By employing a multi-target paradigm, which is more resilient to antibiotic resistance due to simultaneous effect on multiple targets, we have targeted the above key synthases in the FAS-II pathway and validated the identified compounds’ potential as anti-mycobacterial agents using in vitro biological evaluation. Molecular dynamics (MD) simulations further corroborated the potential of active compounds across targets. These molecules present new starting scaffolds, having inhibitory activities of up to 90% with respect to the positive control, for further improvement in terms of their potency as FAS-II pathway inhibitors with the help of medicinal chemistry efforts.
- 4 November 2025
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 39 (2) , 1-14
Mycobacterium tuberculosis FAS-II pathway targeted integrative deep learning based identification of potential anti-tubercular agents
Mycobacterium tuberculosis (Mtb) continues to be one of the major contributors to the global burden of infectious diseases. Many drugs used in the current treatment regime have fallen prey to the puzzling phenomenon of antimicrobial resistance. Despite various attempts, few recent drugs have been developed against the bacterium (Sharma A, Vadodariya PK, Vaddoriya VN, Dhameliya TM (2025) Comprehensive updates on antitubercular endeavors identified in 2023. Synlett 36:2393–2410. https://doi.org/10.1055/a-2595-8032; Patel KI, Saha N, Dhameliya TM, Chakraborti AK (2025) Recent advancements in the quest of Benzazoles as anti-Mycobacterium tuberculosis agents. Bioorg Chem 155:108093. https://doi.org/10.1016/j.bioorg.2024.108093; Dhameliya TM, Bhakhar KA, Gajjar ND, Patel KA, Devani AA, Hirani RV (2022) Recent advancements and developments in search of anti-tuberculosis agents: a quinquennial update and future directions. J Mol Struct 1248:131473. https://doi.org/10.1016/j.molstruc.2021.131473). The proteins involved in Mtb’s fatty acid synthase II (FAS-II) system are suitable drug targets. Many of the enzymes in this pathway, like β-ketoacyl-acyl carrier protein (KasA), 3-oxoacyl-[acyl-carrier-protein] synthase II (KasB) and β-ketoacyl-[acyl-carrier-protein] synthase III (FabH), are indispensable to Mtb but have no counterpart in humans. Here, we present an integrative approach starting with the curation of site specific dataset, exploratory data analysis with multiple machine learning models, virtual screening of compound library with hypertuned artificial neural networks (ANN) having hidden layers, molecular docking studies and in vitro validation to target some of the key elements involved in the mycolic acid chain elongation step during biosynthesis. By employing a multi-target paradigm, which is more resilient to antibiotic resistance due to simultaneous effect on multiple targets, we have targeted the above key synthases in the FAS-II pathway and validated the identified compounds’ potential as anti-mycobacterial agents using in vitro biological evaluation. Molecular dynamics (MD) simulations further corroborated the potential of active compounds across targets. These molecules present new starting scaffolds, having inhibitory activities of up to 90% with respect to the positive control, for further improvement in terms of their potency as FAS-II pathway inhibitors with the help of medicinal chemistry efforts.
- 22 October 2025
- Published by Oxford University Press (OUP) in Journal of Applied Microbiology
- Vol. 136 (11)
Evaluation of the antileishmanial effects and the mode of action of the natural topoisomerase inhibitor shikonin in Leishmania donovani
Aims: Our aim was to evaluate the antileishmanial potential of Shikonin (SKN), a natural topoisomerase inhibitor derived from Lithospermum erythrorhizon, against Leishmania donovani and to elucidate its mechanism of action through physiological, ultrastructural, and in silico studies. Methods and Results: SKN inhibits the in vitro proliferation of both parasite forms, with IC50 values of 3 μM for promastigotes and 0.75 μM for intracellular amastigotes. Using a combination of biophysical and biochemical methods, we found that SKN exerts its cytotoxic effect by generating oxidative stress, mitochondrial dysfunction, and nuclear damage, leading to apoptotic cell death in the parasites. Ultrastructural analysis revealed morphological alterations and apoptotic features in treated parasites, which included mitochondrial swelling and organelle damage, nuclear pyknosis, and pronounced nuclear membrane swelling in the parasites. Since the unique bi-subunit topoisomerase of these parasites has structural differences from the human counterpart and is considered a potential drug target, we performed in-silico molecular docking studies to determine the binding affinity of SKN with topoisomerase 1B (TOP1B). SKN exhibits a stronger binding affinity with L. donovani 1B than the standard topoisomerase inhibitor, camptothecin, forming favorable interactions at the catalytic site. It also shows a lesser binding affinity with human TOP1B than camptothecin. Conclusions: Targeting the Leishmania parasite Topoisomerase with the natural naphthoquinone SKN inhibits parasite proliferation. SKN generates oxidative stress, leading to mitochondrial dysfunction, elevation of cytosolic calcium, and nuclear damage resulting in apoptotic cell death.
- 22 October 2025
- Published by Oxford University Press (OUP) in Journal of Applied Microbiology
- Vol. 136 (11)
Evaluation of the antileishmanial effects and the mode of action of the natural topoisomerase inhibitor shikonin in Leishmania donovani
Aims: Our aim was to evaluate the antileishmanial potential of Shikonin (SKN), a natural topoisomerase inhibitor derived from Lithospermum erythrorhizon, against Leishmania donovani and to elucidate its mechanism of action through physiological, ultrastructural, and in silico studies. Methods and Results: SKN inhibits the in vitro proliferation of both parasite forms, with IC50 values of 3 μM for promastigotes and 0.75 μM for intracellular amastigotes. Using a combination of biophysical and biochemical methods, we found that SKN exerts its cytotoxic effect by generating oxidative stress, mitochondrial dysfunction, and nuclear damage, leading to apoptotic cell death in the parasites. Ultrastructural analysis revealed morphological alterations and apoptotic features in treated parasites, which included mitochondrial swelling and organelle damage, nuclear pyknosis, and pronounced nuclear membrane swelling in the parasites. Since the unique bi-subunit topoisomerase of these parasites has structural differences from the human counterpart and is considered a potential drug target, we performed in-silico molecular docking studies to determine the binding affinity of SKN with topoisomerase 1B (TOP1B). SKN exhibits a stronger binding affinity with L. donovani 1B than the standard topoisomerase inhibitor, camptothecin, forming favorable interactions at the catalytic site. It also shows a lesser binding affinity with human TOP1B than camptothecin. Conclusions: Targeting the Leishmania parasite Topoisomerase with the natural naphthoquinone SKN inhibits parasite proliferation. SKN generates oxidative stress, leading to mitochondrial dysfunction, elevation of cytosolic calcium, and nuclear damage resulting in apoptotic cell death.
- Open Access
- 20 March 2025
- Published by American Chemical Society (ACS) in ACS Bio & Med Chem Au
- Vol. 5 (3) , 387-402
Augmentation of Antimicrobial Activity of Spiniferin by Introducing an Arginine Residue Toward Its Amino Terminus: A Possible Role of Cation−π Interaction
Spiniferin is a 13-mer scorpion-origin antimicrobial peptide having poor antimicrobial activity. To augment Spiniferin’s antimicrobial activity, we enhanced its net positive charge by replacing a glutamic acid residue with an arginine residue toward its amino terminus. We envisaged that a cation−π interaction could be introduced between this arginine residue and the tryptophan residue located near the middle of Spiniferin. This cation−π interaction could promote stronger interaction of the peptide with a negatively charged bacterial membranes, resulting in its increased antimicrobial activity. Though glutamic acid-to-arginine substitution [Spiniferin(E4R)] enhanced both the antimicrobial and toxic properties of Spiniferin, the same replacement with a d-arginine residue [Spiniferin(E4dR)] significantly enhanced its antimicrobial activity against selected Gram-negative/positive bacteria and a MRSA strain while maintaining low hemolytic/cytotoxic properties. Interestingly, Spiniferin(E4dR) analogs, with its aromatic-tryptophan residue substituted with an aromatic phenylalanine or an aliphatic valine residue, and its d-arginine residue replaced with a d-lysine residue, showed much lesser antibacterial activity than Spiniferin(E4dR) or Spiniferin(E4R). The results indicated a crucial role of the tryptophan and l-/d-arginine combination in augmenting the antimicrobial activity of Spiniferin analogs, Spiniferin(E4R) and Spiniferin(E4dR). Spiniferin(E4dR) showed bactericidal properties against selected Gram-positive/negative bacteria. It permeabilized bacterial membranes and induced damages in bacterial membrane organization, suggesting that the bacterial plasma membrane is its target for exhibiting antimicrobial activity. Further, Spiniferin(E4dR) in the intravenous route demonstrated the survival of E. coli ATCC 25922-infected mice and the clearance of bacteria from the visceral organs of these mice. Computational studies showed the requisite distance between the arginine’s cationic side chain and the π-electron site of the tryptophan residue for a possible intramolecular cation−π interaction in Spiniferin(E4dR)/Spiniferin(E4R).
- 20 March 2025
- Published by American Chemical Society (ACS) in ACS Bio & Med Chem Au
- Vol. 5 (3) , 387-402
Open AccessAugmentation of Antimicrobial Activity of Spiniferin by Introducing an Arginine Residue Toward Its Amino Terminus: A Possible Role of Cation−π Interaction
Spiniferin is a 13-mer scorpion-origin antimicrobial peptide having poor antimicrobial activity. To augment Spiniferin’s antimicrobial activity, we enhanced its net positive charge by replacing a glutamic acid residue with an arginine residue toward its amino terminus. We envisaged that a cation−π interaction could be introduced between this arginine residue and the tryptophan residue located near the middle of Spiniferin. This cation−π interaction could promote stronger interaction of the peptide with a negatively charged bacterial membranes, resulting in its increased antimicrobial activity. Though glutamic acid-to-arginine substitution [Spiniferin(E4R)] enhanced both the antimicrobial and toxic properties of Spiniferin, the same replacement with a d-arginine residue [Spiniferin(E4dR)] significantly enhanced its antimicrobial activity against selected Gram-negative/positive bacteria and a MRSA strain while maintaining low hemolytic/cytotoxic properties. Interestingly, Spiniferin(E4dR) analogs, with its aromatic-tryptophan residue substituted with an aromatic phenylalanine or an aliphatic valine residue, and its d-arginine residue replaced with a d-lysine residue, showed much lesser antibacterial activity than Spiniferin(E4dR) or Spiniferin(E4R). The results indicated a crucial role of the tryptophan and l-/d-arginine combination in augmenting the antimicrobial activity of Spiniferin analogs, Spiniferin(E4R) and Spiniferin(E4dR). Spiniferin(E4dR) showed bactericidal properties against selected Gram-positive/negative bacteria. It permeabilized bacterial membranes and induced damages in bacterial membrane organization, suggesting that the bacterial plasma membrane is its target for exhibiting antimicrobial activity. Further, Spiniferin(E4dR) in the intravenous route demonstrated the survival of E. coli ATCC 25922-infected mice and the clearance of bacteria from the visceral organs of these mice. Computational studies showed the requisite distance between the arginine’s cationic side chain and the π-electron site of the tryptophan residue for a possible intramolecular cation−π interaction in Spiniferin(E4dR)/Spiniferin(E4R).
- Open Access
- 15 January 2025
- Published by Oxford University Press (OUP) in Briefings in Functional Genomics
- Vol. 24
Integrative machine learning approach for identification of new molecular scaffold and prediction of inhibition responses in cancer cells using multi-omics data
MDM2 (Mouse Double Minute 2), a fundamental governor of the p53 tumor suppressor pathway, has garnered significant attention as a favorable target for cancer therapy. Recent years have witnessed the development and synthesis of potent MDM2 inhibitors. Despite the fact that numerous MDM2 inhibitors and degraders have been assessed in clinical studies for various human cancers, no FDA-approved drug targeting MDM2 is presently available in the market. Researchers have investigated the effects of various drugs, which are involved in cancer therapies with known mechanisms, on well-characterized cancer cell lines. The prediction of drug inhibition responses becomes crucial to enhance the effectiveness and personalization of cancer treatments. Such findings can provide new perceptions aimed at designing new drugs for targeted cancer therapies. In our current insilico work, a robust response was observed for Idasanutlin in cancer cell lines, indicating the drug’s significant impact on gene expression. We also identified transcriptional response signatures, which were informative about the drug’s mechanism of action and potential clinical application. Further, we applied a similarity search approach for the identification of potential lead compounds from the ChEMBL database and validated them by molecular docking and dynamics studies. The study highlights the potential of incorporating machine learning with omics and single-cell RNA-seq data for predicting drug responses in cancer cells. Our findings could provide valuable insights for improving cancer treatment in the future, particularly in developing effective therapies.
- 15 January 2025
- Published by Oxford University Press (OUP) in Briefings in Functional Genomics
- Vol. 24
Open AccessIntegrative machine learning approach for identification of new molecular scaffold and prediction of inhibition responses in cancer cells using multi-omics data
MDM2 (Mouse Double Minute 2), a fundamental governor of the p53 tumor suppressor pathway, has garnered significant attention as a favorable target for cancer therapy. Recent years have witnessed the development and synthesis of potent MDM2 inhibitors. Despite the fact that numerous MDM2 inhibitors and degraders have been assessed in clinical studies for various human cancers, no FDA-approved drug targeting MDM2 is presently available in the market. Researchers have investigated the effects of various drugs, which are involved in cancer therapies with known mechanisms, on well-characterized cancer cell lines. The prediction of drug inhibition responses becomes crucial to enhance the effectiveness and personalization of cancer treatments. Such findings can provide new perceptions aimed at designing new drugs for targeted cancer therapies. In our current insilico work, a robust response was observed for Idasanutlin in cancer cell lines, indicating the drug’s significant impact on gene expression. We also identified transcriptional response signatures, which were informative about the drug’s mechanism of action and potential clinical application. Further, we applied a similarity search approach for the identification of potential lead compounds from the ChEMBL database and validated them by molecular docking and dynamics studies. The study highlights the potential of incorporating machine learning with omics and single-cell RNA-seq data for predicting drug responses in cancer cells. Our findings could provide valuable insights for improving cancer treatment in the future, particularly in developing effective therapies.
- 1 January 2025
- Published by Springer Nature
- p. 495-514
Databases for Ligand-Based Drug Design and Discovery
- 1 January 2025
- Published by Springer Nature
- p. 495-514
Databases for Ligand-Based Drug Design and Discovery
- 8 December 2024
- Published by Springer Nature in Molecular Diversity
- Vol. 29 (4) , 3077-3100
iDCNNPred: an interpretable deep learning model for virtual screening and identification of PI3Ka inhibitors against triple-negative breast cancer
Triple-negative breast cancer (TNBC) lacks estrogen, progesterone, and HER2 expression, accounting for 15–20% of breast cancer cases. It is challenging due to low therapeutic response, heterogeneity, and aggressiveness. The PI3Ka isoform is a promising therapeutic target, often hyperactivated in TNBC, contributing to uncontrolled growth and cancer cell formation. We have proposed an interpretable deep convolutional neural network prediction (iDCNNPred) system using 2D molecular images to classify bioactivity and identify potential PI3Ka inhibitors. We built Custom-DCNN models and pre-trained models such as AlexNet, SqueezeNet, and VGG19 by using the Bayesian optimization algorithm, and found that our Custom-DCNN model performed better than a pre-trained model with lower complexity and memory usage. All top-performed models were screened with the Maybridge Chemical library to find predictive hit molecules. The screened molecules were further evaluated for protein–ligand interaction with molecular docking and finally 12 promising hits were shortlisted for biological validation using in-vitro PI3K inhibition studies. After biological evaluation, 4 potent molecules with different structural moieties were identified, and these molecules present new starting scaffolds for further improvement in terms of their potency and selectivity as PI3K inhibitors with the help of medicinal chemistry efforts. Furthermore, we also showed the significance of the interpretation and visualization of the model’s predictions by the Grad-CAM technique, enhancing the robustness, transparency, and interpretability of the model’s predictions. The data and script files and prediction run of models used for this study to reproduce the experiment are available in the GitHub repository at https://github.com/ravishankar1307/iDCNNPred.git.
- 8 December 2024
- Published by Springer Nature in Molecular Diversity
- Vol. 29 (4) , 3077-3100
iDCNNPred: an interpretable deep learning model for virtual screening and identification of PI3Ka inhibitors against triple-negative breast cancer
Triple-negative breast cancer (TNBC) lacks estrogen, progesterone, and HER2 expression, accounting for 15–20% of breast cancer cases. It is challenging due to low therapeutic response, heterogeneity, and aggressiveness. The PI3Ka isoform is a promising therapeutic target, often hyperactivated in TNBC, contributing to uncontrolled growth and cancer cell formation. We have proposed an interpretable deep convolutional neural network prediction (iDCNNPred) system using 2D molecular images to classify bioactivity and identify potential PI3Ka inhibitors. We built Custom-DCNN models and pre-trained models such as AlexNet, SqueezeNet, and VGG19 by using the Bayesian optimization algorithm, and found that our Custom-DCNN model performed better than a pre-trained model with lower complexity and memory usage. All top-performed models were screened with the Maybridge Chemical library to find predictive hit molecules. The screened molecules were further evaluated for protein–ligand interaction with molecular docking and finally 12 promising hits were shortlisted for biological validation using in-vitro PI3K inhibition studies. After biological evaluation, 4 potent molecules with different structural moieties were identified, and these molecules present new starting scaffolds for further improvement in terms of their potency and selectivity as PI3K inhibitors with the help of medicinal chemistry efforts. Furthermore, we also showed the significance of the interpretation and visualization of the model’s predictions by the Grad-CAM technique, enhancing the robustness, transparency, and interpretability of the model’s predictions. The data and script files and prediction run of models used for this study to reproduce the experiment are available in the GitHub repository at https://github.com/ravishankar1307/iDCNNPred.git.
- 30 October 2024
- Published by Springer Nature in Journal of Molecular Modeling
- Vol. 30 (11) , 1-21
Pharmacophore-based 3D-QSAR modeling, virtual screening, docking, molecular dynamics and biological evaluation studies for identification of potential inhibitors of alpha-glucosidase
Context Alpha-glucosidase enzyme is considered an important therapeutic target for controlling hyperglycemia associated with type 2 diabetes. Novel scaffolds identified as potential alpha-glucosidase inhibitors from the Maybridge library utilizing pharmacophore modeling, molecular docking and biological evaluation are reported in this manuscript. Method A total of 51 xanthone series scaffolds previously reported as alpha-glucosidase inhibitors were collected and used as training and test sets. These sets were employed to develop and validate a pharmacophore-based 3D-QSAR model with statistically meaningful results using Schrodinger software. The model showed a high F value (F, 80.1) at five component partial least square factors, a high cross-validation coefficient (Q2, 0.66) and a good correlation coefficient (R2, 0.95). Pearson correlation coefficient (r) of 0.8400 indicated a greater degree of confidence in the model. Subsequently, virtual screening was performed with PHASE module of Schrodinger software using the above model to identify novel alpha-glucosidase inhibitors, and mapped compounds were evaluated for their interactions with the protein. The X-ray co-crystallised structure of the alpha-glucosidase protein in complex with acarbose (PDB Code: 5NN8) was used for molecular docking analysis using GLIDE module and a total of eight compounds were further selected for biological evaluation. Molecular dynamics analysis using GROMACS software was performed in the active site of alpha-glucosidase protein to gain insights into binding mechanism of the four active compounds which were finally found to exhibit inhibitory activity in the biological assay.
- 30 October 2024
- Published by Springer Nature in Journal of Molecular Modeling
- Vol. 30 (11) , 1-21
Pharmacophore-based 3D-QSAR modeling, virtual screening, docking, molecular dynamics and biological evaluation studies for identification of potential inhibitors of alpha-glucosidase
Context Alpha-glucosidase enzyme is considered an important therapeutic target for controlling hyperglycemia associated with type 2 diabetes. Novel scaffolds identified as potential alpha-glucosidase inhibitors from the Maybridge library utilizing pharmacophore modeling, molecular docking and biological evaluation are reported in this manuscript. Method A total of 51 xanthone series scaffolds previously reported as alpha-glucosidase inhibitors were collected and used as training and test sets. These sets were employed to develop and validate a pharmacophore-based 3D-QSAR model with statistically meaningful results using Schrodinger software. The model showed a high F value (F, 80.1) at five component partial least square factors, a high cross-validation coefficient (Q2, 0.66) and a good correlation coefficient (R2, 0.95). Pearson correlation coefficient (r) of 0.8400 indicated a greater degree of confidence in the model. Subsequently, virtual screening was performed with PHASE module of Schrodinger software using the above model to identify novel alpha-glucosidase inhibitors, and mapped compounds were evaluated for their interactions with the protein. The X-ray co-crystallised structure of the alpha-glucosidase protein in complex with acarbose (PDB Code: 5NN8) was used for molecular docking analysis using GLIDE module and a total of eight compounds were further selected for biological evaluation. Molecular dynamics analysis using GROMACS software was performed in the active site of alpha-glucosidase protein to gain insights into binding mechanism of the four active compounds which were finally found to exhibit inhibitory activity in the biological assay.
- 9 October 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 281, 136438
Deep convolutional neural network-based identification and biological evaluation of MAO-B inhibitors
- 9 October 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 281, 136438
Deep convolutional neural network-based identification and biological evaluation of MAO-B inhibitors
- 25 April 2024
- Published by Springer Nature in Molecular Diversity
- Vol. 29 (4) , 2865-2880
Integrated machine learning-based virtual screening and biological evaluation for identification of potential inhibitors against cathepsin K
Cathepsin K is a type of cysteine proteinase that is primarily expressed in osteoclasts and has a key role in the breakdown of bone matrix protein during bone resorption. Many studies suggest that the deficiency of cathepsin K is concomitant with a suppression of osteoclast functioning, therefore rendering the resorptive properties of cathepsin K the most prominent target for osteoporosis. This innovative work has identified a novel anti-osteoporotic agent against Cathepsin K by using a comparison of machine learning and deep learning-based virtual screening followed by their biological evaluation. Out of ten shortlisted compounds, five of the compounds (JFD02945, JFD02944, RJC01981, KM08968 and SB01934) exhibit more than 50% inhibition of the Cathepsin K activity at 0.1 μM concentration and are considered to have a promising inhibitory effect against Cathepsin K. The comprehensive docking, MD simulation, and MM/PBSA investigations affirm the stable and effective interaction of these compounds with Cathepsin K to inhibit its function. Furthermore, the compounds RJC01981, KM08968 and SB01934 are represented to have promising anti-osteoporotic properties for the management of osteoporosis owing to their significantly well predicted ADMET properties.
- 25 April 2024
- Published by Springer Nature in Molecular Diversity
- Vol. 29 (4) , 2865-2880
Integrated machine learning-based virtual screening and biological evaluation for identification of potential inhibitors against cathepsin K
Cathepsin K is a type of cysteine proteinase that is primarily expressed in osteoclasts and has a key role in the breakdown of bone matrix protein during bone resorption. Many studies suggest that the deficiency of cathepsin K is concomitant with a suppression of osteoclast functioning, therefore rendering the resorptive properties of cathepsin K the most prominent target for osteoporosis. This innovative work has identified a novel anti-osteoporotic agent against Cathepsin K by using a comparison of machine learning and deep learning-based virtual screening followed by their biological evaluation. Out of ten shortlisted compounds, five of the compounds (JFD02945, JFD02944, RJC01981, KM08968 and SB01934) exhibit more than 50% inhibition of the Cathepsin K activity at 0.1 μM concentration and are considered to have a promising inhibitory effect against Cathepsin K. The comprehensive docking, MD simulation, and MM/PBSA investigations affirm the stable and effective interaction of these compounds with Cathepsin K to inhibit its function. Furthermore, the compounds RJC01981, KM08968 and SB01934 are represented to have promising anti-osteoporotic properties for the management of osteoporosis owing to their significantly well predicted ADMET properties.